Abstract:Tuberculosis (TB), caused by respiratory infection with Mycobacterium tuberculosis , remains a major global health threat. The only licensed TB vaccine, the one-hundred-year-old Bacille Calmette-Guérin has variable efficacy and often provides poor protection against adult pulmonary TB, the transmissible form of the disease. Thus, the lack of an optimal TB vaccine is one of the key barriers to TB control. Recently, the development of highly efficacious COVID-19 vaccines within one year accelerated the vaccine development process in human use, with the notable example of mRNA vaccines and adenovirus-vectored vaccines, and increased the public acceptance of the concept of the controlled human challenge model. In the TB vaccine field, recent progress also facilitated the deployment of an effective TB vaccine. In this review, we provide an update on the current virus-vectored TB vaccine pipeline and summarize the latest findings that might facilitate TB vaccine development. In detail, on the one hand, we provide a systematic literature review of the virus-vectored TB vaccines are in clinical trials, and other promising candidate vaccines at an earlier stage of development are being evaluated in preclinical animal models. These research sharply increase the likelihood of finding a more effective TB vaccine in the near future. On the other hand, we provide an update on the latest tools and concept that facilitating TB vaccine research development. We propose that a pre-requisite for successful development may be a better understanding of both the lung-resident memory T cell-mediated mucosal immunity and the trained immunity of phagocytic cells. Such knowledge could reveal novel targets and result in the innovative vaccine designs that may be needed for a quantum leap forward in vaccine efficacy. We also summarized the research on controlled human infection and ultra-low-dose aerosol infection murine models, which may provide more realistic assessments of vaccine utility at earlier stages. In addition, we believe that the success in the ongoing efforts to identify correlates of protection would be a game-changer for streamlining the triage of multiple next-generation TB vaccine candidates. Thus, with more advanced knowledge of TB vaccine research, we remain hopeful that a more effective TB vaccine will eventually be developed in the near future.

Perspectives on Development and Advancement of New Tuberculosis Vaccines

Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

Induction of an Immune-Protective T-Cell Repertoire with Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans

Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis

Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts

New opportunities in tuberculosis prevention: implications for people living with HIV

Advances in the development of new vaccines for tuberculosis and Brazil's role in the effort forward the end TB strategy

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

End-point definition and trial design to advance tuberculosis vaccine development

Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis

Scaling up interventions to achieve global tuberculosis control: progress and new developments

A Summary on Tuberculosis Vaccine Development-Where to Go?

New developments in tuberculosis diagnosis and treatment

Progress in immunology of tuberculosis and new vaccine development

Tuberculosis Vaccines: Opportunities and Challenges

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

Systems Approach to Tuberculosis Vaccine Development.

Novel Targets for the Development of Tuberculosis Vaccine

Preclinical Progress of Subunit and Live Attenuated Mycobacterium tuberculosis Vaccines: A Review following the First in Human Efficacy Trial

[Diagnosis of tuberculosis in developing countries: new perspectives]